{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:16:15Z","timestamp":1792199775861,"version":"4.4.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.cyto.2015.12.002","type":"journal-article","created":{"date-parts":[[2015,12,14]],"date-time":"2015-12-14T04:00:17Z","timestamp":1450065617000},"page":"87-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Serum proteomic analysis identifies interleukin 16 as a biomarker for clinical response during early treatment of rheumatoid arthritis"],"prefix":"10.1016","volume":"78","author":[{"given":"Atsuko","family":"Murota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Kassai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimpei","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Niki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2015.12.002_b0005","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.cyto.2015.12.002_b0010","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2015.12.002_b0015","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"Lipsky","year":"2000","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.cyto.2015.12.002_b0020","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/annrheumdis-2011-200395","article-title":"Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction","volume":"71","author":"Smolen","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2015.12.002_b0025","first-page":"698192","article-title":"Clinical biomarkers and pathogenic-related cytokines in rheumatoid arthritis","author":"Niu","year":"2014","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.cyto.2015.12.002_b0030","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/rheumatology\/41.1.78","article-title":"Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid synovitis","volume":"41","author":"Klimiuk","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cyto.2015.12.002_b0035","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/rheumatology\/38.11.1081","article-title":"Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis","volume":"38","author":"Posthumus","year":"1999","journal-title":"Rheumatology"},{"key":"10.1016\/j.cyto.2015.12.002_b0040","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/ard.61.2.161","article-title":"Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment","volume":"61","author":"Ribbens","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2015.12.002_b0045","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000295775","article-title":"Age- and gender-dependent changes in connective tissue remodeling: physiological differences in circulating MMP-3, MMP-10, TIMP-1 and TIMP-2 level","volume":"57","author":"Komosinska-Vassev","year":"2011","journal-title":"Gerontology"},{"key":"10.1016\/j.cyto.2015.12.002_b0050","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1007\/s00296-011-2256-5","article-title":"Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI","volume":"32","author":"Kaneko","year":"2012","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.cyto.2015.12.002_b0055","first-page":"279","article-title":"Genomics, proteomics and metabolomics: their emerging roles in the discovery and validation of rheumatoid arthritis biomarkers","volume":"33","author":"Castro-Santos","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.cyto.2015.12.002_b0060","doi-asserted-by":"crossref","first-page":"e35157","DOI":"10.1371\/journal.pone.0035157","article-title":"Protein signature of lung cancer tissues","volume":"7","author":"Mehan","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cyto.2015.12.002_b0065","doi-asserted-by":"crossref","first-page":"e61002","DOI":"10.1371\/journal.pone.0061002","article-title":"Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment","volume":"8","author":"De Groote","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cyto.2015.12.002_b0070","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jalz.2013.09.016","article-title":"Alzheimer\u2019s disease biomarker discovery using SOMAscan multiplexed protein technology","volume":"10","author":"Sattlecker","year":"2014","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.cyto.2015.12.002_b0075","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2015.12.002_b0080","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2015.12.002_b0085","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sj\u00f6gren\u2019s syndrome: a revised version of the European criteria proposed by the American\u2013European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2015.12.002_b0090","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/acr.21591","article-title":"American college of rheumatology classification criteria for Sj\u00f6gren\u2019s syndrome: a data-driven, expert consensus approach in the Sj\u00f6gren\u2019s International collaborative clinical alliance cohort","volume":"64","author":"Shiboski","year":"2012","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"10.1016\/j.cyto.2015.12.002_b0095","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3109\/s10165-004-0338-x","article-title":"Revised Japanese criteria for Sj\u00f6gren\u2019s syndrome (1999): availability and validity","volume":"14","author":"Fujibayashi","year":"2004","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.cyto.2015.12.002_b0100","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2015.12.002_b0105","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","article-title":"A simplified disease activity index for rheumatoid arthritis for use in clinical practice","volume":"42","author":"Smolen","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cyto.2015.12.002_b0110","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score","volume":"7","author":"Aletaha","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.cyto.2015.12.002_b0115","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/art.1780261107","article-title":"Assessment of patient satisfaction in activities of daily living using a modified Stanford health assessment questionnaire","volume":"26","author":"Pincus","year":"1983","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2015.12.002_b0120","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/art.1780220106","article-title":"Serum amyloid A protein in amyloidosis, rheumatic, and enoplastic diseases","volume":"22","author":"Benson","year":"1979","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2015.12.002_b0125","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/rheumatology\/keg037","article-title":"Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis","volume":"42","author":"Green","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cyto.2015.12.002_b0130","first-page":"285","article-title":"The role of interleukin-8 and other cytokines in the pathogenesis of Felty\u2019s syndrome","volume":"13","author":"Meliconi","year":"1995","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.cyto.2015.12.002_b0135","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.49.10.747","article-title":"Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase","volume":"49","author":"Jose","year":"1990","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2015.12.002_b0140","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.0105-2896.2009.00859.x","article-title":"Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis","volume":"233","author":"Bartok","year":"2010","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cyto.2015.12.002_b0145","first-page":"35","article-title":"Enhanced concentrations of interleukin 16 are associated with joint destruction in patients with rheumatoid arthritis","volume":"31","author":"Lard","year":"2004","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.cyto.2015.12.002_b0150","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1002\/(SICI)1521-4141(199809)28:09<2661::AID-IMMU2661>3.0.CO;2-N","article-title":"Interleukin-16, produced by synovial fibroblasts, mediates chemoattraction for CD4+ T lymphocytes in rheumatoid arthritis","volume":"28","author":"Franz","year":"1998","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cyto.2015.12.002_b0155","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10067-006-0312-4","article-title":"Treatment with anti-TNF-alpha antibody infliximab reduces serum IL-15 levels in patients with rheumatoid arthritis","volume":"26","author":"Kageyama","year":"2007","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.cyto.2015.12.002_b0160","first-page":"807","article-title":"Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis","volume":"70","author":"Martel-Pelletier","year":"1994","journal-title":"Lab. Invest."},{"key":"10.1016\/j.cyto.2015.12.002_b0165","first-page":"805","article-title":"Metalloproteases and inhibitors in arthritic diseases","volume":"15","author":"Martel-Pelletier","year":"2001","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.cyto.2015.12.002_b0170","first-page":"13","article-title":"Clinical significance of MMP-3 in patients with rheumatoid arthritis: comparison with other inflammatory markers (IL-6, IL-8)","volume":"51","author":"Hamakawa","year":"2003","journal-title":"Rinsho Byori"},{"key":"10.1016\/j.cyto.2015.12.002_b0175","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cyto.2011.12.010","article-title":"Increased levels of interleukin-33 associated with bone erosion and interstitial lung diseases in patients with rheumatoid arthritis","volume":"58","author":"Xiangyang","year":"2012","journal-title":"Cytokine"},{"key":"10.1016\/j.cyto.2015.12.002_b0180","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.4049\/jimmunol.128.6.2563","article-title":"Modulation of lymphocyte migration by human lymphokines. I. Identification and characterization of chemoattractant activity for lymphocytes from mitogen-stimulated mononuclear cells","volume":"128","author":"Center","year":"1982","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2015.12.002_b0185","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1046\/j.1523-1747.1999.00717.x","article-title":"Expression of the CD4+ cell-specific chemoattractant interleukin-16 in mycosis fungoides","volume":"113","author":"Blaschke","year":"1999","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.cyto.2015.12.002_b0190","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/PL00011171","article-title":"Changes of CD4\/CD8 ratio and interleukin-16 in systemic lupus erythematosus","volume":"19","author":"Matsushita","year":"2000","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.cyto.2015.12.002_b0195","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.4049\/jimmunol.162.7.4293","article-title":"IL-16 as an anti-inflammatory cytokine in rheumatoid synovitis","volume":"162","author":"Klimiuk","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2015.12.002_b0200","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3858\/emm.2008.40.2.237","article-title":"IL-17 induces the production of IL-16 in rheumatoid arthritis","volume":"40","author":"Cho","year":"2008","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.cyto.2015.12.002_b0205","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1165\/ajrcmb.17.2.2750","article-title":"Increased expression of interleukin-16 in bronchial mucosa of subjects with atopic asthma","volume":"17","author":"Laberge","year":"1997","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.cyto.2015.12.002_b0210","first-page":"3","article-title":"Production of IL-16 correlates with CD4+ Th1 inflammation and phosphorylation of axonal cytoskeleton in multiple sclerosis lesions","volume":"26","author":"Skundric","year":"2006","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.cyto.2015.12.002_b0215","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1053\/gast.2000.18164","article-title":"Interleukin 16 is up-regulated in Crohn\u2019s disease and participates in TNBS colitis in mice","volume":"119","author":"Keates","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cyto.2015.12.002_b0220","first-page":"12","article-title":"Interleukin 16 expression in relation to disease activity in rheumatoid arthritis","volume":"28","author":"Blaschke","year":"2001","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.cyto.2015.12.002_b0225","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00296-007-0388-4","article-title":"Etanercept reduces the serum levels of interleukin-23 and macrophage inflammatory protein-3 alpha in patients with rheumatoid arthritis","volume":"28","author":"Kageyama","year":"2007","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.cyto.2015.12.002_b0230","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0162-3109(96)00117-8","article-title":"In vitro and in vivo biological activities of a novel nonpolyglutamable anti-folate, MX-68","volume":"35","author":"Mihara","year":"1996","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.cyto.2015.12.002_b0235","first-page":"2408","article-title":"Resistance of resting 3T6 mouse fibroblasts to methotrexate cytotoxicity","volume":"38","author":"Johnson","year":"1978","journal-title":"Cancer Res."},{"key":"10.1016\/j.cyto.2015.12.002_b0240","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/rheumatology\/34.4.321","article-title":"Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor","volume":"34","author":"Mihara","year":"1995","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.cyto.2015.12.002_b0245","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/1529-0131(200007)43:7<1606::AID-ANR26>3.0.CO;2-O","article-title":"Lack of CD80 expression by fibroblast-like synoviocytes leading to anergy in T lymphocytes","volume":"43","author":"Corrigall","year":"2000","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2015.12.002_b0250","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466615301150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466615301150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T04:25:31Z","timestamp":1692159931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466615301150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":50,"alternative-id":["S1043466615301150"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2015.12.002","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum proteomic analysis identifies interleukin 16 as a biomarker for clinical response during early treatment of rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2015.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}